Novavax, Inc. (NVAX) said the topline results from phase 3 boosting trial for COVID-19 showed that the BA.1 vaccine candidate met the primary strain-change endpoint. The BA.1 vaccine candidate neutralizing responses in those not previously exposed to COVID-19 were greater than those of the prototype vaccine.
"Today's results show that use of our prototype vaccine as a booster induces cross-reactive responses to a broad range of variants with the potential to protect against future strains," said Gregory Glenn, President of Research and Development, Novavax.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News